Corcept Therapeutics
CORT
119.60
+0.03
+0.03%
Corcept Therapeutics
US · CORT
#1285 by market cap
Listed 1970
119.60
+0.03
+0.03%
Live - 5344 symbols - heartbeat 205s ago
· 2026-10-08 08:25
Pre-market
118.00
-1.34%
After-hours
119.60
0.00%
- Market cap
- 12.93B
- P/E (TTM)i
- 265.78
- P/Bi
- 18.32
- EPSi
- 0.82
- Div yieldi
- 0.00%
- 52W posi
- 93%
Reader sentiment
Are you bullish or bearish on CORT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 43.70, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +12.79% YoY
Margins
- Gross margin
- 98.30%
- Operating margin
- 5.88%
- Net margin
- 12.89%
Key ratios & quality
- Altman Z-Scorei
- 43.70
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 251.25M | 306.49M | 353.87M | 365.98M | 401.86M | 482.38M | 675.04M | 761.41M |
| Gross profit | 246.03M | 300.98M | 348.29M | 360.70M | 396.47M | 475.89M | 664.16M | 748.43M |
| Selling & admin expenses | 81.29M | 100.36M | 105.33M | 122.36M | 152.85M | 184.26M | 280.32M | 448.73M |
| Research & development | 75.25M | 89.02M | 114.76M | 113.86M | 130.99M | 184.35M | 246.89M | 254.91M |
| Operating profit | 89.50M | 111.61M | 128.20M | 124.48M | 112.63M | 107.28M | 136.95M | 44.80M |
| Pretax profit | 92.15M | 116.68M | 131.60M | 125.01M | 116.19M | 124.56M | 161.49M | 66.46M |
| Tax | 16.74M | 22.50M | 25.59M | 12.49M | 14.77M | 18.42M | 20.28M | -33.19M |
| Net profit | 75.41M | 94.18M | 106.01M | 112.51M | 101.42M | 106.14M | 141.21M | 99.65M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.60 | 0.77 | 0.85 | 0.89 | 0.87 | 0.94 | 1.23 | 0.82 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 157.21M | 194.43M | 207.64M | 202.13M | 164.90M | 256.15M |
| Gross profit | 154.81M | 191.00M | 203.04M | 199.58M | 162.02M | 252.09M |
| Selling & admin expenses | 90.66M | 103.85M | 123.98M | 130.24M | 145.36M | 156.90M |
| Research & development | 60.74M | 60.47M | 68.85M | 64.86M | 66.27M | 53.89M |
| Operating profit | 3.42M | 26.68M | 10.22M | 4.49M | -49.60M | 41.30M |
| Pretax profit | 9.62M | 31.69M | 15.24M | 9.91M | -44.72M | 45.93M |
| Tax | -10.93M | -3.46M | -4.43M | -14.38M | -12.95M | 2.94M |
| Net profit | 20.55M | 35.15M | 19.67M | 24.29M | -31.76M | 42.99M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.17 | 0.29 | 0.16 | 0.20 | -0.30 | 0.36 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 236.82M | 307.36M | 478.50M | 266.46M | 499.25M | 458.64M | 471.60M | 485.46M |
| Cash & ST investments | 206.76M | 275.96M | 440.70M | 223.54M | 431.67M | 368.22M | 383.33M | 372.15M |
| Inventory | 4.73M | 5.42M | 4.91M | 4.99M | 6.10M | 7.73M | 12.41M | 12.87M |
| Total assets | 311.69M | 412.31M | 571.73M | 423.76M | 583.43M | 621.52M | 840.55M | 836.65M |
| Total current liabilities | 35.57M | 38.84M | 47.49M | 47.54M | 72.49M | 104.51M | 140.77M | 166.09M |
| Short-term debt | -- | 1.56M | 2.05M | 526.00K | 1.14M | 151.00K | 829.00K | 1.08M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 35,812,000.00 | 41,130,000.00 | 48,393,000.00 | 47,950,000.00 | 81,588,000.00 | 114,812,000.00 | 160,964,000.00 | 188,846,000.00 |
| Total equity | 275.88M | 371.18M | 523.34M | 375.81M | 501.84M | 506.71M | 679.59M | 647.81M |
| Retained earnings | -117.74M | -23.56M | 82.46M | 194.97M | 296.39M | 402.53M | 543.74M | 643.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 438.50M | 443.11M | 541.13M | 485.46M | 426.03M | 439.68M |
| Cash & ST investments | 322.76M | 342.23M | 421.68M | 372.15M | 338.18M | 308.20M |
| Inventory | 14.37M | 12.28M | 12.35M | 12.87M | 12.89M | 13.19M |
| Total assets | 846.46M | 801.72M | 823.61M | 836.65M | 814.88M | 888.70M |
| Total current liabilities | 143.07M | 144.66M | 172.27M | 166.09M | 149.19M | 153.80M |
| Short-term debt | 984.00K | 1.02M | 1.05M | 1.08M | 1.63M | 1.92M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 163,170,000.00 | 165,929,000.00 | 191,705,000.00 | 188,846,000.00 | 176,894,000.00 | 182,926,000.00 |
| Total equity | 683.29M | 635.79M | 631.90M | 647.81M | 637.99M | 705.78M |
| Retained earnings | 564.28M | 599.43M | 619.10M | 643.39M | 611.63M | 654.61M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 115.67M | 136.12M | 151.97M | 167.89M | 120.32M | 126.68M | 198.30M | 142.00M |
| Depreciation & amortization | 236.00K | 2.17M | 2.24M | 3.48M | 3.45M | 2.36M | 1.34M | 1.89M |
| Free cash flow | 115.37M | 135.03M | 150.73M | 167.42M | 119.91M | 126.54M | 196.12M | 141.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -23.66M | -30.98M | -9.95M | -295.99M | 0 | -145.43M | 0 | 0 |
| Ending cash balance | 41.63M | 31.27M | 76.19M | 77.62M | 66.33M | 135.55M | 127.67M | 120.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 4.77M | 44.30M | 54.48M | 38.45M | -16.77M | 33.54M |
| Depreciation & amortization | 462.00K | 469.00K | 477.00K | 482.00K | 598.00K | 863.00K |
| Free cash flow | 4.67M | 44.24M | 54.48M | 38.40M | -16.97M | 31.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 90.82M | 103.75M | 125.14M | 120.50M | 109.99M | 112.29M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 32.31 | 29.11 | 23.70 | 25.03 | 23.08 | 20.92 | 23.56 | 14.79 |
| ROA %i | 28.34 | 26.02 | 21.55 | 22.60 | 20.11 | 17.51 | 19.11 | 11.71 |
| ROIC %i | 31.37 | 27.55 | 22.94 | 24.84 | 22.33 | 17.98 | 19.72 | 12.24 |
| 5-year avg ROE %i | -54.04 | 22.99 | 44.69 | 44.26 | 26.65 | 24.37 | 23.26 | 21.48 |
| EBIT margin %i | 35.62 | 36.41 | 36.23 | 34.01 | 28.03 | 22.24 | 20.29 | 5.88 |
| FCF / sales %i | 45.92 | 44.06 | 42.59 | 45.75 | 29.84 | 26.31 | 29.02 | 18.62 |
| Current ratioi | 6.66 | 7.91 | 10.07 | 5.60 | 6.89 | 4.39 | 3.35 | 2.92 |
| Quick ratioi | 6.31 | 7.62 | 9.83 | 5.28 | 6.58 | 4.05 | 3.11 | 2.60 |
| Debt / assetsi | 0.00 | 0.84 | 0.45 | 0.12 | 0.20 | 0.02 | 0.83 | 0.73 |
| LT debt / equityi | -- | 0.51 | 0.10 | -- | -- | -- | 0.90 | 0.78 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 70.96 | 55.62 | 30.51 | 13.36 | 9.45 | 10.88 | 22.64 | 23.74 |
| Net income CAGR (3Y) %i | -- | 126.18 | -6.36 | 14.27 | 2.50 | 0.04 | 7.87 | -0.58 |
| FCF CAGR (3Y) %i | 233.40 | 95.05 | 35.55 | 13.22 | -3.88 | -5.66 | 5.42 | 5.74 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 21.53 | 21.43 | 16.47 | 14.79 | 7.07 | 8.09 |
| ROA %i | 17.64 | 17.41 | 13.02 | 11.71 | 5.62 | 6.42 |
| ROIC %i | 17.31 | 18.32 | 13.64 | 12.24 | 5.15 | 6.23 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.17 | 14.24 | 8.85 | 5.88 | -1.07 | 0.77 |
| FCF / sales %i | 25.85 | 25.18 | 22.01 | 18.62 | 15.62 | 12.87 |
| Current ratioi | 3.07 | 3.06 | 3.14 | 2.92 | 2.86 | 2.86 |
| Quick ratioi | 2.69 | 2.81 | 2.85 | 2.60 | 2.53 | 2.50 |
| Debt / assetsi | 0.81 | 0.82 | 0.77 | 0.73 | 1.18 | 1.06 |
| LT debt / equityi | 0.86 | 0.88 | 0.84 | 0.78 | 1.26 | 1.06 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Hypercortisolism Products is the largest reported line at 81.43% of revenue, across 2 reported segments.
- The next-largest line, Lifyorli, is a distant second at 18.57% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Hypercortisolism Products81.43%
Lifyorli18.57%
Quote time 2026-10-08 08:25:27 · For reference only, not investment advice and not tailored to your situation.